Work

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-162447

Authors: Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn

Institutions: University of California, Los Angeles, University of Rochester Medicine, Florida Cancer Specialists & Research Institute, Tulane University, AstraZeneca (United Kingdom), AstraZeneca (United States), National Institutes of Health, Center for Cancer Research, Sarah Cannon, Tennessee Oncology

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310108528

FWCI: 0.704

Cites:

Cited by: 5

Related to: 10